Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Appropriators Worry About US FDA Gene Therapy, Complex Generic Approval Pace

Executive Summary

In report language, the committee funds more CBER cell and gene therapy staff for rare diseases and suggests AI be considered to speed up complex generic assessments.

You may also be interested in...



Beyond Aduhelm: OIG Review Will Put FDA’s Entire Accelerated Approval Program Under Microscope

HHS Inspector General’s timeline means Congress won’t have findings to use during upcoming user fee renewal debate; ‘review’ is not an ‘investigation’ which could come with potentially more damning legal consequences for the agency.

Aduhelm Invades Senate Committee’s COVID-19 Hearing

Woodcock again defends the decision, saying Congress intended accelerated approval for those situations.

House Appropriations Committee Embraces Clinical Trial Issues In FY 2022 US FDA Budget Bill

Report language includes several mentions of improving trial diversity and recruitment, while bill offers a 5% increase in funding.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel